Tag Archives: entrepreneurship

Confirmed Investors Attending RESI Europe 2026 — Early Bird Rates End Friday 

18 Feb

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is pleased to welcome investors from across the globe to RESI Europe 2026, taking place March 23 in Lisbon, Portugal, with virtual partnering scheduled for March 24–25 and 30–31. This premier event is designed to connect active early-stage investors with innovative life science companies and foster the partnerships that move promising science toward commercialization.

Early Bird rates expire this Friday, and those who register now will save €200. With partnering open March 2, this is the ideal time to secure your place and ensure access to the full RESI Europe experience.

RESI Europe convenes a highly engaged community of venture investors, corporate venture arms, family offices, strategic partners, and non-dilutive funding organizations, all actively evaluating new opportunities across therapeutics, diagnostics, medical devices, and digital health. The event is structured to maximize meaningful interactions, offering curated partnering, targeted networking, and direct visibility into emerging companies seeking capital and strategic collaboration.

For investors focused on sourcing new opportunities, building syndicates, and staying ahead of early-stage innovation trends, RESI Europe provides a concentrated and efficient environment to connect with founders, fellow investors, and ecosystem leaders from Europe, North America, and beyond. Conversations initiated at RESI frequently lead to follow-on diligence, partnerships, and investments that extend well beyond the event itself.

Confirmed RESI Europe Investors

Register before the Early Bird deadline this Friday to secure €200 in savings and confirm your participation alongside a growing global investor community.

Register for RESI Europe

Tags: , , , , , , , , , , , ,

Investor Fireside Chat in Barcelona: Building Momentum Toward RESI Europe  

10 Feb

By Brenda Olmos, Business Development Manager, Global Tech Hub and Sponsorship, LSN

In preparation for RESI Europe, the global life-science investment community will gather in Barcelona for an exclusive Investor Fireside Chat designed to equip founders and innovators with practical fundraising insights ahead of the conference.

Event Details
Date: February 18
Time: 15:00–19:00
Location: Hotel H10 Art Gallery, C/ Enric Granados 62, Barcelona

RSVP: https://form.jotform.com/260354367670157

This focused pre-RESI event brings together leading investors and pioneering entrepreneurs for an afternoon of strategy, storytelling, and networking within Barcelona’s vibrant innovation ecosystem.

Attendees will hear directly from investor Luis Pareras of InVivo Partners, joined by two standout founders shaping the future of neurotechnology and drug delivery: Ana Maiques of Neuroelectrics and Meritxell Teixidó of Gate2Brain. Together, they will share candid perspectives on what investors look for, how founders can position their companies effectively, and the realities of raising capital in today’s life-science landscape.

Speakers
Luis-Pareras Ana-Maiques Meritxell Teixidó
Luis ParerasFounder and Managing Partner
InVivo Partners		 Ana MaiquesCEO & CoFounder
Neuroelectrics		 Meritxell TeixidóCEO & CSO
Gate2Brain

The program will open with a hands-on Fundraising Bootcamp led by author and serial entrepreneur Dennis Ford (Boston), offering practical guidance on refining your pitch, navigating investor conversations, and building a compelling funding strategy. The session is designed to provide actionable takeaways that participants can immediately apply as they prepare for RESI Europe and beyond.

The afternoon will conclude with networking drinks, giving attendees the opportunity to connect with peers, investors, and ecosystem leaders in an informal setting.

Whether you are actively raising capital or planning your next financing round, this event offers a valuable opportunity to gain insight, build relationships, and align your strategy ahead of RESI Europe.

Register for RESI Europe

Tags: , , , , ,

Life Science Nation Names Dealflow.eu as a Title Sponsor of RESI Europe Lisbon; Highlights EIC Participation Pathway

10 Feb

By Greg Mannix, VP, EMEA Business Development, LSN

New collaboration strengthens access for European life science innovators to engage global capital investors and licensing partners

Cambridge, MA and Lisbon, Portugal 

Life Science Nation (LSN) announced today a partnership with Dealflow.eu, naming the organization as a Title Sponsor of RESI Europe Lisbon. The collaboration supports the identification and preparation of high-potential European life science innovators and strengthens pathways for companies—where eligible—to leverage European Innovation Council (EIC) reimbursement mechanisms to participate in the RESI partnering ecosystem.

Dealflow.eu operates as a European innovation matchmaking and readiness platform, surfacing high-potential life sciences and deep-tech companies and supporting their engagement with global investors and strategic partners. Through this collaboration, Dealflow.eu will route a curated cohort of life science companies to RESI Europe Lisbon, positioning them in front of a global audience of investors and partners actively seeking early-stage opportunities.

RESI Europe Lisbon serves as the global activation layer of the Life Science Nation partnering ecosystem, connecting emerging technologies with investors and strategic partners through curated matchmaking, investor panels, and the Innovator’s Pitch Challenge. Unlike broad innovation showcases, RESI is purpose-built for early-stage life sciences partnering and capital formation, enabling qualified investors and partners to engage with technologies prepared for global scrutiny.

As part of this collaboration, Dealflow.eu will support eligible companies in accessing available reimbursement mechanisms—such as those offered through EIC programs, where applicable—to offset a portion of RESI Europe registration costs. This helps reduce participation barriers and expands access for promising European life sciences innovators to connect with global capital and strategic partner networks.

“This partnership strengthens the pathway from early innovation to global partnering,” said Dennis Ford, Founder and CEO of Life Science Nation. “Dealflow.eu operates upstream, identifying and preparing high-potential innovators for investor engagement. RESI operates downstream, providing the global activation environment where capital investors and strategic partners connect with emerging technologies. At the same time, programs such as those offered through the EIC can help support company participation and readiness along that journey.”

“We see RESI Europe as a highly complementary activation platform for the Dealflow.eu network,” said André Moraes Sarmento, Dealflow.eu. “Our mission is to connect high-potential innovators with investors, corporates, and strategic partners. This collaboration gives life science companies direct access to a global audience of qualified investors and licensing partners actively seeking early-stage technologies.”

The collaboration also includes coordinated programming at RESI Europe Lisbon, dedicated visibility opportunities for participating innovators, pre-conference preparation support, and continued alignment to strengthen pathways from European innovation to global market engagement.

RESI Europe Lisbon will take place in Lisbon, Portugal, bringing together global investors, strategic partners, and early-stage life sciences innovators across therapeutics, devices, diagnostics, digital health, and enabling technologies.

About Life Science Nation

Life Science Nation operates a global partnering and matching ecosystem that connects early-stage life sciences companies with qualified capital investors and licensing partners worldwide. Its platforms include the RESI Conference Series, LSN Labs entrepreneurial education and readiness programs, and global partnering campaign infrastructure.

About Dealflow.eu

Dealflow.eu is a European innovation matchmaking and readiness platform connecting high-potential innovators with investors, corporates, and strategic partners across Europe and globally.

Media Contact
Caitlin Dolegowski
Marketing Manager
Life Science Nation
c.dolegowski@lifesciencenatio.com
719-229-9290

Tags: , , , , , , , , , ,

Europe Doesn’t Have a Capital Problem. It Has a Translation Problem 

10 Feb

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Across Europe, early-stage life science innovation isn’t held back by a lack of capital. It’s held back by a lack of translation. Brilliant ideas emerge every day from universities, startups, and labs, but too few of them cross the chasm into fundable, scalable ventures. Not because investors are uninterested, but because the signal is still forming. 

That is the gap RESI Europe is built to fill.

RESI Europe is intentionally focused on companies in the earliest stages of formation: seed, Series A, and Series B. In practical terms, that means seed financings up to $2M, Series A rounds up to $10M, and Series B rounds up to $50M. RESI is also cross-domain by design, connecting drugs, devices, diagnostics, and digital health under one roof so that cross-silo innovation can actually be seen and underwritten. These companies are not yet de-risked. They are still shaping their data, refining their narrative, and clarifying what kind of asset they are becoming. 

Unlike broad partnering events that are optimized for finished stories, RESI Europe’s product is filtration, not exposure. The investors and partners who participate specialize in early risk and engage before all the questions are answered, because that is when the partnership has the greatest leverage. And RESI does this at a registration cost typically around half of what many large European partnering conferences charge, making serious early-stage partnering accessible rather than exclusive. 

Partnering at this stage is not about acceleration.

It is about preparation. 

Europe does not need more capital flowing into the same mature assets. It needs a mechanism to translate potential into signal and the clarity to underwrite early-stage opportunities. Without that translation, meetings happen but decisions do not. Not because the science is weak, but because the story is still illegible.​ 

RESI Europe exists to make early innovation readable and to bring investors, strategics, and entrepreneurs together around the translational work that must happen before Phase II-level legibility is possible. 

Capital follows clarity.

Clarity requires translation.

That is what RESI Europe is built to deliver. 

Register for RESI Europe

Tags: , , , , , , , , , , , ,

New EU Webinar Series – From Discovery to Decision: Making Early-Stage Life Science Legible to Capital

10 Feb

By Max Braht, Director of Business Development, LSN

Max-Braht-Headshot

Across Europe, early-stage life science innovation is not constrained by a lack of capital—it is constrained by a lack of translation. Breakthrough science continues to emerge from universities, hospitals, and startups across the continent, yet too few assets successfully transition from discovery into opportunities the global market can underwrite.

To address this gap, Life Science Nation is launching a new three-part seminar series tailored specifically for the European life science ecosystem. The program focuses on the critical space between discovery and investment decision-making—where promising science often stalls before capital ever has the chance to engage.

Designed for founders, investors, accelerators, universities, public agencies, and ecosystem leaders, the series centers on companies at the seed, Series A, and Series B stages—where signal is still forming and legibility matters more than exposure.

What the series will explore

Session I — Tuesday, February 17 | 10:00 AM ET / 4:00 PM CET  – Sign Up

Why Solid Science Fails to Translate Before Capital Even Considers It
An exploration of how early-stage assets stall long before diligence begins—and why the issue is typically a failure to tell an investable story, not a lack of compelling science.

Session II — Tuesday, February 24 | 10:00 AM ET / 4:00 PM CET – Sign Up

Legibility, Signal, and the Real Work Between Seed and Series B
What European and global investors actually require to underwrite early-stage risk, and how signal is formed across scientific, regulatory, and commercial dimensions.

Session III — Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET – Sign Up

Partnering Is Not Exposure. It Is Filtration
How different partnering environments serve different stages of development, and how European companies can avoid wasting time and momentum by engaging the wrong forum too early.

This is not a fundraising seminar and not a pitch workshop. It is a practical framework for understanding how early-stage European innovation becomes readable—to capital, to strategic partners, and to the global market.

Register for RESI Europe

Tags: , , , , ,

Why Early-Stage Companies Need the Right Partnering Room 

3 Feb

By Tony Jones, CEO, One Nucleus (Special Guest Contributor)

Every January, JPM Week serves as a useful reference point for the global life sciences industry. It brings together capital, companies, and partners at an unmatched scale with so many co-located events. Processing how to spend their time at JPM Week is a great exercise for companies to evaluate their wider investment and dealmaking plans given not all partnering and investment environments are the same.

How to choose the best event for their company is a frequent question we receive at One Nucleus from our network and having spent time with a range of UK and European companies trying to focus their cash and time resources to optimise chances of success. JPM Week is an obvious hub to target in the US, of course, provided the homework and planning is done to try and be in the right place at the right time. Having spent time with UK and European executives at JPM, it is clear that for early-stage teams in particular, the experience they describe reinforces an important lesson. Access to an event or partnering platform alone is insufficient and depends on whether it is designed to support where a company actually is on its journey and what it needs next.

In the absence of a JPM Week, although the nascent London Life Sciences Week is trying to evolve in that direction, early-stage European companies seeking investment have a far less obvious starting point. The larger, bio-partnering events play an important role and are extremely efficient for biopharma companies of all stages in that capacity. Equally, the larger investment events play a somewhat effective role but are perhaps more suited to later-stage companies with established programs, clear clinical development strategies and well-defined buyers. This is not a reflection of scale, attendee mix or necessarily cost which is a relative term, it is a question of fit and whether that is the right place to be at the right time to justify the budget spend.

What early-stage companies can need is a different kind of forum that prioritises readiness, qualification, and stage-appropriate engagement over shots on goal. Taking a hands-on approach to curating the attending companies and investors, can create a better fit and hence increase the chances of success for all concerned. The early-stage dominance of the European sector means Europe needs this part of the conference jigsaw, providing quality connection to both local investors and channels to global investors active in their space and stage. Translating strong science into something global investors and licensing partners requires preparation, clarity around risk, and disciplined positioning, issues many young companies need guidance to work through.

That is why platforms such as RESI Europe matter in the European context. As an ecosystem organisation, One Nucleus sees the additional, not just competing value the LSN platform brings to our members, providing options over how and when to leverage different forums.

Register for RESI Europe

Tags: , , , , , , , , ,

Hear From a RESI JPM 2026 Title Sponsor BioMetas

3 Feb

By Simon Hua, Chairman, BioMetas (Special Guest Contributor)

One of the most valuable perspectives we can share with the RESI community comes directly from the organizations that choose to invest in early stage innovation. At RESI JPM 2026, Title Sponsor BioMetas took part across partnering, project discussions, and collaboration with emerging biotech companies and investors, offering a clear view into how sponsors engage within the RESI ecosystem.

As Life Science Nation looks ahead to upcoming RESI conferences in 2026, sponsorship continues to be an opportunity for organizations to connect early with innovative companies, participate in targeted partnering, and build relationships that extend well beyond the conference itself. To learn more about RESI sponsorship opportunities, please contact us at resi@lifesciencenation.com

Below is BioMetas’ reflection on their experience at RESI JPM 2026, originally published on LinkedIn.

BioMetas Attends RESI JPM 2026, Focusing on Early Innovation and Industry Collaboration

RESI JPM 2026 was held in San Francisco on January 12–13, with additional online one-to-one partnering sessions on January 14 and January 19–20. As a key investment and business-matching platform during J.P. Morgan Healthcare Conference (JPM) week, the conference focuses on early- and growth-stage life science projects, bringing together biotech companies, investors, and industry partners from around the world. As a Title Sponsor, BioMetas participated deeply in the overall conference ecosystem. Leveraging its one-stop CRO platform and innovative incubation and investment model, BioMetas engaged in targeted discussions with international biotech companies and investment institutions around the core needs of early-stage innovation projects, including R&D efficiency, capital structure optimization, and industry resource alignment, exploring diversified pathways for R&D collaboration and industry co-development.

The conference centered on highly targeted one-to-one partnering meetings, complemented by investor roundtables, innovation project pitch and selection sessions, and multiple themed workshops. Topics spanned drug development, medical devices, diagnostics, and digital health, forming a multidimensional engagement framework of “project showcase – capital connection – industry collaboration,” enabling innovative projects to build high-quality connections with potential investors and partners within a short timeframe.

During the conference, BioMetas focused on the practical needs of early-stage projects across critical preclinical stages, including protein and antibody production, in vitro and in vivo efficacy studies, tumor and immunology-related disease model development, and DMPK. BioMetas discussed project advancement strategies in depth with multiple innovative companies. With an integrated technical system covering target validation, molecular and cellular functional studies, animal efficacy testing, and PK/safety evaluation, BioMetas provides scalable, IND-enabling, end-to-end R&D support for innovative projects across different technological approaches.

In parallel, based on its EFS (Equity for Service) collaboration model, BioMetas explored more forward-looking partnership mechanisms with selected projects from seed stage to rapid growth stage. By exchanging part of the services for a small equity stake, combined with necessary cash investment, BioMetas helps early teams initiate R&D quickly while keeping financial pressure manageable, and achieve key milestones that build a stronger technical foundation for subsequent financing, licensing, or M&A. In today’s more rational capital environment, where efficiency and data quality are increasingly emphasized, a collaborative model integrating “services + capital + industry resources” is becoming an important accelerator for early-stage projects.

RESI JPM 2026 was not only a stage for showcasing innovation, but also an efficient collaboration platform connecting technology, capital, and industry resources. Through its precise one-to-one partnering mechanism, the conference significantly improved communication efficiency, enabling companies at different stages to access more targeted collaboration opportunities within limited time.

Through this participation, BioMetas further strengthened its dual role in the global innovation ecosystem: on one hand, providing reliable and scalable R&D support to global clients; on the other hand, actively engaging in early value co-creation and pursuing earlier-stage, deeper collaborations with high-quality projects.

Looking ahead, BioMetas will continue to expand collaboration with global biotech companies, investors, and industry partners through international conferences and industry networks, accelerating the translation and industrialization of innovative research outcomes and therapeutic programs, and contributing stronger technical and collaborative support to the global biopharmaceutical innovation ecosystem.

About RESI
Through its RESI partnering events and global collaboration programs, Life Science Nation connects entrepreneurs with global investors and strategic partners, accelerating financing for early-stage life science companies.

About BioMetas
BioMetas is a globally leading one-stop CRO platform for innovative drug R&D, bringing together top domestic CRO resources and an international, highly experienced technical team. With efficient and innovative expertise, rigorous scientific standards, and a comprehensive quality management system, BioMetas provides compliant, high-quality, and customized end-to-end preclinical R&D solutions. Its services cover the full process from drug discovery to IND for both small-molecule drugs and biologics.

Register for RESI Europe

Tags: , , , , , ,

← Older Entries